poisar

Stocks · News reference

CERo Therapeutics Activates UC Davis as Clinical Trial and Manufacturing Site

Fiscal.ai

CERo Therapeutics has added the University of California, Davis as a clinical trial site for its CERTAIN-T study, which will also serve as the primary manufacturing location for CER-1236.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Globenewswire IncNa

    SRX Global Provides Update on Engineered T-Cell Strategy Following Pfizer–Starna Licensing Agreement

    SRX Global commented on industry activity in engineered T-cell therapies following Pfizer's $330 million upfront deal with Starna Therapeutics for pre-IND CAR-T programs. SRX is proceeding with its pending acquisition of CERo Therapeutics, which is advancing CER-1236, a clinical-stage engineered T-cell therapy currently in Phase 1/1b CERTAIN-T trials with seven patients dosed and no dose-limiting toxicities reported.

  2. Globenewswire IncNa

    SRX Global and CERO 1236, a Wholly-Owned SPV, Enter into Definitive Agreement to Acquire CERo Therapeutics, an Innovative Cellular Immunotherapy Company Developing CER 1236 for Hematologic Malignancies

    SRX Global Inc. announced a definitive agreement to acquire CERo Therapeutics Holdings, Inc., an innovative cellular immunotherapy company developing CER-1236 for hematologic malignancies. The acquisition will be structured through a wholly-owned SPV (CERO 1236) to avoid diluting existing SRX shareholders. The transaction is expected to accelerate CER-1236's clinical development and provide CERo with enhanced access to capital and operational resources. CERo has treated six patients in its Phase 1 CERTAIN-T trial with no dose-limiting toxicities observed at increased dose levels.